Supernus SVP awarded 3,750 performance share units

SUPERNUS PHARMACEUTICALS, INC. reported an insider equity award for senior vice president and Chief Technology Operations Officer Frank Mottola.

Accepted by SEC EDGAR 03/03/2026 - 04:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. reported an insider equity award for senior vice president and Chief Technology Operations Officer Frank Mottola. He acquired 3,750 Performance Share Units at a stated price of $0.00 per unit, leaving him with 3,750 such derivative securities held directly after the transaction.

According to the footnote, these Performance Share Units were originally awarded on February 23, 2023, with individual performance objectives for a defined performance period established on June 12, 2023. A portion of that award vested upon achievement of these objectives, and the reported acquisition reflects this vesting-based grant.

Insider Trade Summary

Grant/Award: 3,750 shares

Grant/Award 1 txn

Insider Mottola Frank

Role SVP, Chief Tech. Ops. Officer

Type	Security	Shares	Price	Value
Grant/Award	Performance Share Unit	3,750	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 3,750 contracts (Direct)

Holdings Before and After: Performance Share Unit, 0 to 3,750 contracts (Direct)

Footnotes (1)

1. F1. On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SUPN report for Frank Mottola?

Supernus Pharmaceuticals reported that SVP and Chief Technology Operations Officer Frank Mottola acquired 3,750 Performance Share Units at a stated price of $0.00 per unit, reflecting a vesting-based equity award tied to earlier performance conditions.

How many Supernus (SUPN) Performance Share Units were involved?

The filing shows 3,750 Performance Share Units involved in the transaction. After this award, Frank Mottola directly holds a total of 3,750 derivative securities of this type, all tied to his compensation at Supernus Pharmaceuticals.

Was the SUPN insider transaction a purchase or an equity award?

The transaction was an equity award, not a market purchase. It is coded as a grant or other acquisition of 3,750 Performance Share Units at $0.00 per unit, representing compensation rather than an open-market buy or sell of common stock.

What performance conditions were linked to the SUPN Performance Share Units?

The Performance Share Units were awarded on February 23, 2023, with individual performance objectives for a defined performance period established on June 12, 2023. A portion of this award vested only after those individual performance objectives were achieved.

How did this Form 4 change Frank Mottola’s SUPN holdings?

Following the reported transaction, Frank Mottola holds 3,750 Performance Share Units directly. The filing does not indicate any dispositions, only the vesting-related acquisition of these derivative securities as part of his compensation package.

What role does the insider in this SUPN Form 4 hold?

The reporting person, Frank Mottola, serves as Senior Vice President and Chief Technology Operations Officer at Supernus Pharmaceuticals. The 3,750 Performance Share Units reported are part of his incentive compensation based on individual performance objectives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mottola Frank

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Tech. Ops. Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	02/28/2026		A		3,750		(1)	(1)	Common Stock	3,750	$0	3,750	D

Explanation of Responses:

1. On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.